Elke, Adam, and Gabor join TWiV to discuss their work on Lloviu virus, a filovirus, including recovery of infectious virus from a DNA copy of the genome and from Schreiber’s bats in Hungary.

This episode of TWiV is focused on COVID-19 vaccines and antibodies: who should get boosters, whether a variant matched mRNA vaccine is superior to a historical vaccine, and how the interval between vaccination and infection influences the quality of the antibody response.

In COVID-19 clinical update #110, Dr. Griffin covers hospital admissions during variant outbreaks, viral load in vaccinated and unvaccinated individuals, predictive capacity of symptoms in children, comparison of antigen tests, incidence of myocarditis after vaccination, steroids during replication phase, Paxlovid efficacy and safety, fluvoxamine, sabizabutin, colchicine, and prevalence of infection in Africa.

TWiV explains why this season’s influenza vaccine is not protecting against mild to moderate disease caused by H3N2 virus, and that antibody-dependent entry of SARS-CoV-2 into monocytes is a major contributor to severe COVID-19.

In COVID-19 clinical update #109, Daniel Griffin discusses cardiac complications after infection or vaccination, long COVID in children, fourth vaccine dose in Israel, no need for fourth vaccine dose in EU, dexamethasone dosing, immunomodulation therapy, MIS outcomes in children, US long COVID effort launched, and herd immunity.

TWiV reveals an ACE2-dependent sarbecovirus from Russian bats that is not inhibited by anti-SARS-CoV-2 antibodies, and a modified vaccinia virus Ankara vectored vaccine that protects nonhuman primates from Delta infection.

In COVID-19 clinical update #107, Daniel Griffin reviews vaccine booster doses, at-home testing, transmission in ferrets, improving indoor air quality, trials of BCG, ivermectin, and fluvoxamine, vaccination during pregnancy, mRNA vaccines and Fc functions, anti-platelet and aspirin therapy and a trial of prone positioning.